Latest News

JOINT STATEMENT ISSUED BY PAW PRINT GENETICS AND OPTIGEN

OptiGen® grants Paw Print Genetics an exclusive sub-license for use of patents for genetic testing of dogs in the USA and Canada for:

progressive retinal atrophy (PRA-prcd)

Collie eye anomaly (CEA)

Congenital stationary night blindness (CSNB)

Retinal dysplasia/Oculoskeletal dysplasia (RD/OSD)

OptiGen, a New York State-based company and Paw Print Genetics, a Washington State-based company, have decided to settle patent litigation filed by OptiGen in August, 2013. The patents at issue in the case are owned by Cornell University and are licensed to OptiGen for canine genetic testing related to progressive retinal atrophy (PRA-prcd), Collie eye anomaly (CEA), congenital stationary night blindness (CSNB), and Retinal dysplasia/Oculoskeletal dysplasia (RD/OSD).

Both OptiGen and Paw Print Genetics offer inherited disease testing to identify carriers and affected dogs for a variety of different canine genetic conditions. The terms of the settlement were not disclosed. 

Based on the settlement, Paw Print Genetics now holds the exclusive North American sublicense from OptiGen for PRA-prcd, CEA, CSNB and RD/OSD testing in the U.S. and Canada. With the sublicense in place, the Orthopedic Foundation for Animal has agreed to allow registry of these tests performed by Paw Print Genetics.

For more information on OptiGen, visit: https://www.optigen.com

For more information on Paw Print Genetics, visit: https://pawprintgenetics.com

Contacts:

Sue Pearce-Kelling, M.S.
President and Manager, OptiGen, LLC
767 Warren Road, Suite 300
Ithaca, New York 14850
suepk@optigen.com

 

Lisa G Shaffer, PhD
CEO, Genetic Veterinary Sciences, Inc., DBA Paw Print Genetics
850 E Spokane Falls Blvd., Suite 200
Spokane, WA 99202
lshaffer@pawprintgenetics.com